1. [Development and prospects of bispecific antibodies for multiple myeloma].
- Author
-
Yuda J
- Subjects
- Humans, B-Cell Maturation Antigen immunology, Drug Development, Antibodies, Bispecific therapeutic use, Antibodies, Bispecific immunology, Multiple Myeloma drug therapy, Multiple Myeloma immunology
- Abstract
Patients with triple-class refractory multiple myeloma once had a poor prognosis, but recently developed bispecific antibodies (bsAbs) targeting B-cell maturation antigen (BCMA), G protein-coupled receptor 5D (GPRC5D), and Fc receptor-homolog 5 (FcRH5) have shown significant clinical activity in these patients. However, responses to bsAbs are not universal, and resistance often develops during therapy. Mechanisms that mediate resistance may be tumor-intrinsic or immune-dependent. Tumor-intrinsic factors include antigen loss (biallelic or functional) due to deletion or mutation of target genes, increased soluble BCMA (for BCMA targeting bsAbs), high tumor burden, and extramedullary disease. Immune-mediated resistance highly depends on T cell fitness and the resistant immune environment. This article describes bispecific antibodies against multiple myeloma that are currently being developed.
- Published
- 2024
- Full Text
- View/download PDF